Personalis and Tempus AI Expand Partnership, Boosting Personalis Stock

Personalis, Tempus AI expand commercial relationship (NASDAQ:PSNL)

Personalis (NASDAQ:PSNL) and Tempus AI (TEM) said they will expand their commercial relationship. Tempus AI will invest ~$36M into Personalis, and will also accelerate its commercialization efforts over the first two years. Under the agreement, Tempus has agreed to exercise its existing warrants to purchase 9.2M shares in accordance with their terms at an average purchase price of $2.00 and to purchase an additional 3.5M shares at a price per share of $5.07. Tempus will own ~19.3% percent of Personalis' outstanding common stock following the closing of the transactions. Under the agreement, Personalis will increase the quantity of patient samples it will accept over the corresponding period. More on Personalis Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript Seeking Alpha's Quant Rating on Personalis Historical earnings data for Personalis Financial information for Personalis

Personalis shares gain as BTIG raises target to $7 By Investing.com

On Friday, BTIG updated its analysis of Personalis Inc (NASDAQ:PSNL), a company specializing in advanced genomic sequencing. The firm increased the stock's price target to $7.00 from the previous $5.50, while reiterating a Buy rating. This adjustment comes in the wake of Personalis amending its collaboration terms with Tempus AI, leading to a significant uptick in the company's stock value. Personalis had a productive discussion with BTIG on Friday morning, revealing that Tempus AI is experiencing "exceptionally strong demand" for its NeXT Personal test, leading to an increase in the minimum number of tests to be conducted during its early commercial launch. Additionally, Tempus exercised warrants to purchase 9.2 million Personalis shares at an average price of $2.00 per share, a strategic move considering the current trading price of the stock. Further bolstering the partnership, Tempus agreed to acquire an additional 3.5 million shares of Personalis at $5.07 each, matching the closing price on Thursday. This transaction not only reinforces the recent positive momentum in Personalis's stock but also potentially establishes a new support level around the $5 mark. Tempus's actions have elevated its stake in Personalis to approximately 19%, while also injecting $36 million in cash into Personalis, enhancing its cash position to a pro-forma total of $123 million. The financial infusion is seen as a de-risking factor for Personalis, providing a more stable financial platform for the company's operations. Despite the recent appreciation in stock value, Personalis's shares are currently trading at 2.2 times BTIG's 2025 revenue estimate of $83 million. This valuation is slightly below the peer group average of 2.4 times and significantly under the historical average multiples, which range between approximately 3 to 7 times. BTIG's reinforced Buy rating and the new price target reflect confidence in Personalis's growth trajectory and market position. In other recent news, Personalis Inc. has reported a significant increase in its second quarter revenue, reaching $22.6 million, a 35% year-over-year growth. This increase was primarily driven by a 117% expansion in its biopharma business. Following these results, Personalis adjusted its full-year revenue guidance, now expecting revenues to fall between $79 million and $81 million. In addition, Tempus AI, Inc. has invested $36 million in Personalis, strengthening their commercial relationship. This investment follows a collaboration agreement made previously, focusing on ultra-sensitive tumor-informed minimal residual disease (MRD) testing. This partnership has seen a surge in demand, leading both companies to accelerate their joint efforts. BTIG, a prominent financial services firm, has maintained a Buy rating for Personalis and raised the stock's price target to $5.50. This decision was influenced by the company's robust performance in the second quarter. Personalis' recent developments, including growth in its oncology clinical diagnostic testing service and orders for its NeXT Personal MRD test, have solidified its position in the genomic sequencing and analytics space. In light of BTIG's updated analysis on Personalis Inc, recent data from InvestingPro offers additional insights into the company's financial health and stock performance. Personalis holds more cash than debt on its balance sheet, which aligns with the increased financial stability mentioned in the article. This is a positive sign for investors looking for companies with solid liquidity. Additionally, two analysts have revised their earnings upwards for the upcoming period, indicating an optimistic outlook on the company's future financial performance. InvestingPro data shows that Personalis has experienced a significant return over the last week, with a 55.52% price total return. Moreover, the stock has seen a strong return over the last month and three months, with 152.24% and 263.44% price total returns, respectively. This supports the article's point about the stock's recent positive momentum. Despite the impressive short-term returns, analysts do not anticipate the company will be profitable this year, which investors should consider when evaluating the long-term prospects of Personalis. For those interested in delving deeper into Personalis's performance and potential, there are additional InvestingPro Tips available at https://www.investing.com/pro/PSNL, which provide a comprehensive analysis of the company's financials and market position.